Viewing Study NCT02716766


Ignite Creation Date: 2025-12-24 @ 4:01 PM
Ignite Modification Date: 2026-02-22 @ 4:15 PM
Study NCT ID: NCT02716766
Status: COMPLETED
Last Update Posted: 2020-04-10
First Post: 2016-03-09
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
Sponsor: The University of Hong Kong
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Hepatocellular View
None Secondary View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Sorafenib View
None Drug Therapy View